CliffBio
small molecule

PYLARIFY

PIFLUFOLASTAT F-18

Loss of exclusivityJune 2037latest FDA-listed patent expiry
CompanyProgenics Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand namePYLARIFY
Active ingredientPIFLUFOLASTAT F-18
Strength50ML (1-80mCi/ML)
Dosage formSOLUTION
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalMay 2021
Marketing statusRX

Listed patents

PatentExpiresType
10947197June 2037substance, product
11851407June 2037substance, product
8778305September 2030substance, product
9861713July 2029substance, product
12070513July 2029substance, product
8487129November 2027substance, product

Regulatory exclusivity

CodeExpires
NCEMay 2026

More from Progenics Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.